Humanized anti CXCR4 antibodies for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-9249223-B2
Application number	US-201113637198-A
Country	US
Kind code	B2
Filing date	Mar 30, 2011
Priority date	Mar 30, 2010
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.

First claim

The invention claimed is:

1. A humanized antibody capable of binding specifically to CXCR4, or a CXCR4-binding fragment of same, wherein said humanized antibody, or CXCR4-binding fragment of same, comprises:
heavy and light chains, said heavy chain having complementarity-determining regions (CDRs) consisting of CDR-H1, CDR-H2 and CDR-H3, and the said light chain having CDRs consisting of CDR-L1, CDR-L2 and CDR-L3, wherein said CDR-H1, CDR-H2 and CDR-H3 comprise respectively the sequences of SEQ ID Nos. 4, 5 and 6, and said CDR-L1, CDR-L2 and CDR-L3 comprise respectively the sequences of SEQ ID Nos. 7, 8 and 9; and
said heavy chain having a variable region of sequence selected from SEQ ID Nos. 85 and 87 and said light chain having a variable region of sequence selected from SEQ ID Nos. 86 and 88.

2. A humanized antibody, or CXCR4-binding fragment of same, according to claim 1 , characterized in that it comprises a heavy chain of sequence selected from SEQ ID Nos. 89 and 91 and a light chain of sequence selected from SEQ ID Nos. 90 and 92.

3. A composition comprising the humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 and an excipient.

4. A pharmaceutical composition comprising as an active ingredient a compound consisting of a humanized antibody, or a CXCR4-binding fragment of same, according to any one of claims 1 and 2 , and a pharmaceutically acceptable excipient and/or diluent.

5. A combination product, comprising the composition of claim 4 and an anti-tumor antibody other than an antibody directed against CXCR4, wherein the combination product is in a single dosage form or in separate dosage forms, administered simultaneously, separated, or in extended fashion.

6. A combination product, comprising the composition of claim 4 and a cytotoxic/cytostatic agent, a cellular toxin and/or a radioisotope, wherein the combination product is in a single dosage form or in separate dosage forms, administered simultaneously, separated, or in extended fashion.

7. A kit comprising at least a humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 .

8. A kit comprising at least a humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 , wherein said antibody or CXCR4-binding fragment of the same, is labeled.

9. A humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 , selected from:
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain variable region of sequence of SEQ ID No. 85, and a light chain variable region of sequence of SEQ ID No. 86;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain variable region of sequence of SEQ ID No. 87, and a light chain variable region of sequence of SEQ ID No. 86;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain variable region of sequence of SEQ ID No. 85, and a light chain variable region of sequence of SEQ ID No. 88;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain variable region of sequence of SEQ ID No. 87, and a light chain variable region of sequence of SEQ ID No. 88.

10. A humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 , selected from:
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain of sequence of SEQ ID No. 89, and a light chain of sequence of SEQ ID No. 90;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain of sequence of SEQ ID No. 91, and a light chain of sequence of SEQ ID No. 90;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain of sequence of SEQ ID No. 89, and a light chain of sequence of SEQ ID No. 92;
a humanized antibody, or a CXCR4-binding fragment of same, characterized in that it comprises a heavy chain of sequence of SEQ ID No. 91, and a light chain of sequence of SEQ ID No. 92.

11. An isolated nucleic acid molecule characterized in that it is selected among the following nucleic acids:
a) a nucleic acid, DNA or RNA, coding for a humanized antibody, or for a CXCR4-binding fragment of same, according to claim 1 ; and
b) a nucleic acid complementary to a nucleic acid as defined in a).

12. A vector composed of a nucleic acid according to claim 11 .

13. A host cell comprising a vector according to claim 12 .

14. A method for producing a humanized antibody, or a CXCR4-binding fragment of same, characterized in that said method comprises:
the culture in a medium of and the suitable culture conditions for a host cell according to claim 13 ; and
the recovery of said antibody, or one of its functional fragments, thus produced from the culture medium or from said cultured cells.

15. A method of treating cancer, comprising administering to a subject in need of treatment for cancer a therapeutically effective amount of an isolated antibody according to claim 1 .

16. The method according to claim 15 , wherein said cancer is a cancer chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, multiple myeloma, ovarian cancer, pancreatic cancer, and colon cancer.

17. A process of detecting in vitro the presence and/or the location of a CXCR4 expressing tumor in a subject, wherein said process comprises the steps of:
(a) contacting a sample from the subject with a humanized antibody, or a CXCR4-binding fragment of same, according to claim 1 ; and
(b) detecting the binding of said antibody with the sample.

18. A method of treating cancer, comprising administering to a subject in need of treatment for cancer a therapeutically effective amount of a pharmaceutical composition according to claim 4 .

19. A method of treating cancer, comprising administering to a subject in need of treatment for cancer a therapeutically effective amount of a combination product according to claim 5 .

20. A method of treating cancer, comprising administering to a subject in need of treatment for cancer a therapeutically effective amount of a combination product according to claim 6 .

21. The method according any one of claims 18 - 20 , wherein said cancer is a cancer chosen from prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, multiple myeloma, ovarian cancer, pancreatic cancer, and colon cancer.

Assignees

• Klinguer-Hamour Christine
• Jouhanneaud Alexandra
• Grenier-Caussanel Véronique
• Pf Medicament

Inventors

• Klinguer-Hamour Christine
• Jouhanneaud Alexandra
• Grenier-Caussanel Véronique

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/18

  for HIV · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• C07K14/475

  Growth factors; Growth regulators · CPC title